ID,Sentence,Label,Prep_sentence,Stemmed_sentence
1,The results in 2nd line treatment show an ORR of 33% with some patients having durable responses resulting in an apparent PFS plateau,0,results line treatment show orr patients durable responses resulting apparent pfs plateau,result line treatment show orr patient durabl respons result appar pf plateau
2,The long duration of response and high durable response rate observed after 6-month minimum follow-up is further substantiated by the 12-months minimum follow-up analysis,0,long duration response high durable response rate observed month minimum follow substantiated months minimum follow analysis,long durat respons high durabl respons rate observ month minimum follow substanti month minimum follow analysi
3,The median OS time in the updated results exceeded 1 year,1,median os time updated results exceeded year,median os time updat result exceed year
4,"Therefore, the clinical benefit in 2nd line treatment is considered clinically meaningful and the magnitude of the effect is significant compared to chemotherapy",0,therefore clinical benefit line treatment considered clinically meaningful magnitude effect significant compared chemotherapy,therefor clinic benefit line treatment consid clinic meaning magnitud effect signific compar chemotherapi
5,"The data provided in 1st line, although preliminary, showed activity of avelumab in mMCC in terms of response rate, and evidence of a similar durable response from the small subset of patients with a longer follow-up compared to 2nd line treatment",0,data provided line although preliminary showed activity avelumab mmcc terms response rate evidence similar durable response small subset patients longer follow compared line treatment,data provid line although preliminari show activ avelumab mmcc term respons rate evid similar durabl respons small subset patient longer follow compar line treatment
6,"Taking into account the intrinsic limitation of single arm studies, the rarity of the disease and the challenges to compare the results with data from historical controls and in the literature, the currently available data are deemed to support the efficacy of avelumab in both pre-treated and chemotherapy-naïve patients",0,taking account intrinsic limitation single arm studies rarity disease challenges compare results data historical controls literature currently available data deemed support efficacy avelumab pre treated chemotherapy naïve patients,take account intrins limit singl arm studi rariti diseas challeng compar result data histor control literatur current avail data deem support efficaci avelumab pre treat chemotherapi naïv patient
7,This medicinal product has been authorised under a so-called ‘conditional approval’ scheme,1,medicinal product authorised called conditional approval scheme,medicin product authoris call condit approv scheme
8,This means that further evidence on this medicinal product is awaited,2,means evidence medicinal product awaited,mean evid medicin product await
9,The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary,1,european medicines agency review new information medicinal product least every year smpc updated necessary,european medicin agenc review new inform medicin product least everi year smpc updat necessari
10,The CHMP considers the following measures necessary to address the missing efficacy data for 1st line treatment in the context of a conditional MA:,2,chmp considers following measures necessary address missing efficacy data line treatment context conditional,chmp consid follow measur necessari address miss efficaci data line treatment context condit
11,"In order to confirm the efficacy for chemotherapy-naïve treated patients, the MAH should submit the final results of study EMR 100070-003 – Part B",1,order confirm efficacy chemotherapy naïve treated patients mah submit final results study emr part b,order confirm efficaci chemotherapi naïv treat patient mah submit final result studi emr part b
12,The final results of the study should be submitted by 30th January 2020,1,final results study submitted january,final result studi submit januari
13,The CHMP considers that additional supportive data on efficacy will be provided also from the following post-authorisation safety study: ,1,chmp considers additional supportive data efficacy provided also following post authorisation safety study,chmp consid addit support data efficaci provid also follow post authoris safeti studi
14,• PASS: German real-world cohort study should be submitted as additional PhV activity to address the missing information of safety and efficacy in immune compromised patients,2,pass german real world cohort study submitted additional phv activity address missing information safety efficacy immune compromised patients,pass german real world cohort studi submit addit phv activ address miss inform safeti efficaci immun compromis patient
15,The safety data collected at an earlier data cut remains consistent with longer follow up ,0,safety data collected earlier data cut remains consistent longer follow,safeti data collect earlier data cut remain consist longer follow
16,No major concerns have been identified in the updated analysis,0,major concerns identified updated analysis,major concern identifi updat analysi
17,The safety of avelumab in the proposed indication appears to be acceptable and manageable with the recommendations as proposed in the SmPC and the RMP,0,safety avelumab proposed indication appears acceptable manageable recommendations proposed smpc rmp,safeti avelumab propos indic appear accept manag recommend propos smpc rmp
18,The safety risks associated with immune related adverse reactions are managed through additional risk minimisation activities implemented in the form of educational materials that will inform HCPs and patients on how to identify and properly handle suspected immune related ADRs,1,safety risks associated immune related adverse reactions managed additional risk minimisation activities implemented form educational materials inform hcps patients identify properly handle suspected immune related adrs,safeti risk associ immun relat advers reaction manag addit risk minimis activ implement form educ materi inform hcp patient identifi properli handl suspect immun relat adr
19,The CHMP considers the following measures necessary to address issues related to safety: ,2,chmp considers following measures necessary address issues related safety,chmp consid follow measur necessari address issu relat safeti
20,• PASS: German real-world cohort study should be submitted as additional PhV activity to address the missing information of safety and efficacy in immune compromised patients,2,pass german real world cohort study submitted additional phv activity address missing information safety efficacy immune compromised patients,pass german real world cohort studi submit addit phv activ address miss inform safeti efficaci immun compromis patient
21,Biosimilarity of CT-P10 and MabThera is considered demonstrated based on the efficacy data.,0,biosimilarity ct mabthera considered demonstrated based efficacy data,biosimilar ct mabthera consid demonstr base efficaci data
22,"In the pivotal RA trial, efficacy results in terms of DAS28 and ACR were shown to be comparable between CT-P10 and MabThera.",0,pivotal ra trial efficacy results terms acr shown comparable ct mabthera,pivot ra trial efficaci result term acr shown compar ct mabthera
23,"In addition, PK data discussed support the extrapolation to the autoimmune indications MPA/GPA.",0,addition pk data discussed support extrapolation autoimmune indications mpa gpa,addit pk data discuss support extrapol autoimmun indic mpa gpa
24,"The objectives of study CT-P10 3.3 were to demonstrate similarity in pharmacokinetics and non-inferiority in efficacy of CT-P10 to Rituxan as primary endpoints when coadministered with CVP in patients with advanced FL; these objectives have been met and furthermore, extrapolation in the context of NHL and CLL indications is acceptable.",0,objectives study ct demonstrate similarity pharmacokinetics non inferiority efficacy ct rituxan primary endpoints coadministered cvp patients advanced fl objectives met furthermore extrapolation context nhl cll indications acceptable,object studi ct demonstr similar pharmacokinet non inferior efficaci ct rituxan primari endpoint coadminist cvp patient advanc fl object met furthermor extrapol context nhl cll indic accept
25,The overall safety profile of CT-P10 appeared roughly similar to that of the reference product although the pooled incidences of AEs and SAEs were generally lower for the reference products.,1,overall safety profile ct appeared roughly similar reference product although pooled incidences aes saes generally lower reference products,overal safeti profil ct appear roughli similar refer product although pool incid ae sae gener lower refer product
26,"Therefore, the available safety data are considered supportive of biosimilarity between CT-P10 and MabThera.",0,therefore available safety data considered supportive biosimilarity ct mabthera,therefor avail safeti data consid support biosimilar ct mabthera
27,"Most common reported events were infections, infusion related reactions.",1,common reported events infections infusion related reactions,common report event infect infus relat reaction
28,The frequencies and nature of the adverse events were in line with those reported for the innovator MabThera/Rituxan in the RA and NLH study populations.,0,frequencies nature adverse events line reported innovator mabthera rituxan ra nlh study populations,frequenc natur advers event line report innov mabthera rituxan ra nlh studi popul
29,"Although dataset of AFL patients has been updated, data are still considered very limited to reach firm conclusion about safety proflie.",2,although dataset afl patients updated data still considered limited reach firm conclusion safety proflie,although dataset afl patient updat data still consid limit reach firm conclus safeti profli
30,Additional safety data from maintenance study period CT-P10 3.3 and follow-up period should be provided (see RMP).,2,additional safety data maintenance study period ct follow period provided see rmp,addit safeti data mainten studi period ct follow period provid see rmp
31,The planned extension studies CT-P10 3.2 (RA) CT-P10 3.3 (AFL) and CT-P10 3.4 (LTBFL) listed in the RMP will provide additional long term safety data.,1,planned extension studies ct ra ct afl ct ltbfl listed rmp provide additional long term safety data,plan extens studi ct ra ct afl ct ltbfl list rmp provid addit long term safeti data
32,A summary of the literature with regard to clinical data of Daptomycin Hospira and justifications that the product is essentially similar in properties with regards to safety and efficacy of the reference product was provided and was accepted by the CHMP.,0,summary literature regard clinical data daptomycin hospira justifications product essentially similar properties regards safety efficacy reference product provided accepted chmp,summari literatur regard clinic data daptomycin hospira justif product essenti similar properti regard safeti efficaci refer product provid accept chmp
33,This is in accordance with the relevant guideline and additional clinical studies were not considered necessary.,0,accordance relevant guideline additional clinical studies considered necessary,accord relev guidelin addit clinic studi consid necessari
34,The superiority to placebo was demonstrated for both dupilumab doses as monotherapy or in combination with TCS in AD patients who are insufficiently controlled with topical therapies alone.,0,superiority placebo demonstrated dupilumab doses monotherapy combination tcs ad patients insufficiently controlled topical therapies alone,superior placebo demonstr dupilumab dose monotherapi combin tc ad patient insuffici control topic therapi alon
35,No significant additional benefit was observed with weekly dosing versus Q2W dosing (300 mg s.c) in the overall population.,1,significant additional benefit observed weekly dosing versus dosing mg sc overall population,signific addit benefit observ weekli dose versu dose mg sc overal popul
36,"Therefore, the CHMP endorsed the proposed dose of 300 mg every other week (Q2W) with a loading dose of 600 mg on day 1.",1,therefore chmp endorsed proposed dose mg every week loading dose mg day,therefor chmp endors propos dose mg everi week load dose mg day
37,"Based on the presented and available data, dupilumab has been found to have an acceptable safety profile.",0,based presented available data dupilumab found acceptable safety profile,base present avail data dupilumab found accept safeti profil
38,"With regard to TEAE profile, no meaningful qualitative and quantitative differences were seen as to short-term and long-term treatment as well as to the dose regimen.",1,regard teae profile meaningful qualitative quantitative differences seen short term long term treatment well dose regimen,regard teae profil meaning qualit quantit differ seen short term long term treatment well dose regimen
39,"As questions still remain on the long term safety, ongoing open-label extension studies are being undertaken that will provide further data.",2,questions still remain long term safety ongoing open label extension studies undertaken provide data,question still remain long term safeti ongo open label extens studi undertaken provid data
40,The applicant provided six pivotal studies to support this application.,1,applicant provided six pivotal studies support application,applic provid six pivot studi support applic
41,"Only 3 pivotal randomized double-blind multicentre placebo controlled studies (Parsons and Mulholland 1987, Mulholland et al 1990 and Parsons et al 1993) among the 6 pivotal studies met their primary endpoint “GRA” and some secondary endpoints such as pain.",2,pivotal randomized double blind multicentre placebo controlled studies parsons mulholland mulholland et al parsons et al among pivotal studies met primary endpoint gra secondary endpoints pain,pivot random doubl blind multicentr placebo control studi parson mulholland mulholland et al parson et al among pivot studi met primari endpoint gra secondari endpoint pain
42,"Based on the primary meta-analysis conducted by the applicant including the six pivotal studies, the estimated benefit differences reached about 13% (ITT and as reported).",1,based primary meta analysis conducted applicant including six pivotal studies estimated benefit differences reached itt reported,base primari meta analysi conduct applic includ six pivot studi estim benefit differ reach itt report
43,This benefit difference (PPS versus placebo) reached 17% when excluding 2 pivotal studies (Holm-Bentzen et al 1987 and Nickel et al 2015) with the lowest response rates and with a population less homogeneous than in the four other clinical studies (mixing both broad IC/BPS),1,benefit difference pps versus placebo reached excluding pivotal studies holm bentzen et al nickel et al lowest response rates population less homogeneous four clinical studies mixing broad ic bps,benefit differ pp versu placebo reach exclud pivot studi holm bentzen et al nickel et al lowest respons rate popul less homogen four clinic studi mix broad ic bp
44,"Indeed, this benefit difference was mainly driven by the statistically significant results of the three pivotal studies Parsons et al 1993, Mulholland et al 1990 and Parsons and Mulholland 1987 including patients falling within ESSIC classification 2X to 3C.",1,indeed benefit difference mainly driven statistically significant results three pivotal studies parsons et al mulholland et al parsons mulholland including patients falling within essic classification,inde benefit differ mainli driven statist signific result three pivot studi parson et al mulholland et al parson mulholland includ patient fall within essic classif
45,Furthermore according to the meta-analysis of the four pivotal studies performed in patients meeting the ESSIC classification 2X to 3C the pooled response rate under PPS treatment was 2-fold higher than the pooled response rate under placebo (“GRA” primary endpoint and also pain and urgency)and efficacy of PPS was considered sufficiently demonstrated in this population,0,furthermore according meta analysis four pivotal studies performed patients meeting essic classification pooled response rate pps treatment fold higher pooled response rate placebo gra primary endpoint also pain urgencyand efficacy pps considered sufficiently demonstrated population,furthermor accord meta analysi four pivot studi perform patient meet essic classif pool respons rate pp treatment fold higher pool respons rate placebo gra primari endpoint also pain urgencyand efficaci pp consid suffici demonstr popul
46,"Overall, the safety profile of PPS is not considered of concern.",0,overall safety profile pps considered concern,overal safeti profil pp consid concern
47,"Due to the heparin-like structure of PPS, a weak anticoagulant effect was observed with PPS and patients with risk factors for increased bleeding (undergoing invasive procedures, having underlying coagulopathy or taking anticoagulants) should be carefully evaluated for haemorrhage during the treatment.",2,due heparin like structure pps weak anticoagulant effect observed pps patients risk factors increased bleeding undergoing invasive procedures underlying coagulopathy taking anticoagulants carefully evaluated haemorrhage treatment,due heparin like structur pp weak anticoagul effect observ pp patient risk factor increas bleed undergo invas procedur underli coagulopathi take anticoagul care evalu haemorrhag treatment
48,This risk is adequately addressed in various sections of the SmPC and as important identified risk in the RMP.,0,risk adequately addressed various sections smpc important identified risk rmp,risk adequ address variou section smpc import identifi risk rmp
49,Based on the presented bioequivalence study the test formulation Emtricitabine/Tenofovir disoproxil Krka d.d. 200mg/245mg film coated tablets of Krka d.d. Slovenia is considered bioequivalent with the reference Truvada 200mg/245mg film coated tablets manufactured by Gilead Sciences Intl. Ltd. Ireland MA holder: Gilead Sciences UK.,0,based presented bioequivalence study test formulation emtricitabine tenofovir disoproxil krka dd film coated tablets krka dd slovenia considered bioequivalent reference truvada film coated tablets manufactured gilead sciences intl ltd ireland holder gilead sciences uk,base present bioequival studi test formul emtricitabin tenofovir disoproxil krka dd film coat tablet krka dd slovenia consid bioequival refer truvada film coat tablet manufactur gilead scienc intl ltd ireland holder gilead scienc uk
50,The application contains an adequate review of published clinical data and the bioequivalence has been shown between Granpidam and Viagra® 100 mg film-coated tablets.,0,application contains adequate review published clinical data bioequivalence shown granpidam mg film coated tablets,applic contain adequ review publish clinic data bioequival shown granpidam mg film coat tablet
51,A biowaiver for the 20 mg strength is considered acceptable.,0,biowaiver mg strength considered acceptable,biowaiv mg strength consid accept
52,Based on the presented bioequivalence study Granpidam is considered bioequivalent with Viagra (reference product used).,0,based presented bioequivalence study granpidam considered bioequivalent viagra reference product used,base present bioequival studi granpidam consid bioequival viagra refer product use
53,"The results of study 084-09 with 100mg formulation can be extrapolated to other strengths 20mg, according to conditions in the Guidelines.",0,results study formulation extrapolated strengths according conditions guidelines,result studi formul extrapol strength accord condit guidelin
54,The results presented on efficacy support the biosimilarity claim between the test product SB5 and the reference product EU Humira.,0,results presented efficacy support biosimilarity claim test product reference product eu humira,result present efficaci support biosimilar claim test product refer product eu humira
55,The number of subjects is sufficient for comparing the safety profile of the biosimilar candidate SB5 and reference medicinal product EU-Humira and studying the safety of a biosimilar product for up to one year.,0,number subjects sufficient comparing safety profile biosimilar candidate reference medicinal product eu humira studying safety biosimilar product one year,number subject suffici compar safeti profil biosimilar candid refer medicin product eu humira studi safeti biosimilar product one year
56,"Broadly, the number, severity and type of TEAEs, SAEs, AEs of special interest, treatment discontinuations due to AEs, laboratory findings were comparable between SB5 and Humira and mirroring the safety profile as described in the SmPC of Humira.",0,broadly number severity type teaes saes aes special interest treatment discontinuations due aes laboratory findings comparable humira mirroring safety profile described smpc humira,broadli number sever type teae sae ae special interest treatment discontinu due ae laboratori find compar humira mirror safeti profil describ smpc humira
57,"The frequency of related AEs, severity of AEs and AESIs remained similar for the group who transitioned from Humira to SB5 at week 24.",0,frequency related aes severity aes aesis remained similar group transitioned humira week,frequenc relat ae sever ae aesi remain similar group transit humira week
58,"More detailed data on injection site reactions, hypersensitivity and anaphylactic reactions were requested in order to allow a thorough assessment of this issue both in subjects with and without ADAs.",2,detailed data injection site reactions hypersensitivity anaphylactic reactions requested order allow thorough assessment issue subjects without adas,detail data inject site reaction hypersensit anaphylact reaction request order allow thorough assess issu subject without ada
59,The submitted additional analyses further support the comparability of the safety profile of SB5 and Humira.,0,submitted additional analyses support comparability safety profile humira,submit addit analys support compar safeti profil humira
60,"With regard to immunogenicity, the incidence and titre distribution of ADAs were compared and seemed similar for SB5 and Humira, with about half of all subjects developing neutralising antibodies in each treatment group.",0,regard immunogenicity incidence titre distribution adas compared seemed similar humira half subjects developing neutralising antibodies treatment group,regard immunogen incid titr distribut ada compar seem similar humira half subject develop neutralis antibodi treatment group
61,No worsening of the immunogenicity profile was observed after transitioning from Humira to SB5.,0,worsening immunogenicity profile observed transitioning humira,worsen immunogen profil observ transit humira
62,There was no clinical efficacy study performed to support the biosimilarity claim.,1,clinical efficacy study performed support biosimilarity claim,clinic efficaci studi perform support biosimilar claim
63,"In light of established biosimilarity on quality level, the remaining uncertainty that the safety profile of Inhixa and Clexane differs significantly was considered low enough to conclude on similarity.",0,light established biosimilarity quality level remaining uncertainty safety profile inhixa clexane differs significantly considered low enough conclude similarity,light establish biosimilar qualiti level remain uncertainti safeti profil inhixa clexan differ significantli consid low enough conclud similar
64,"For the purpose of the clinical biosimilarity exercise for biosimilar insulin products, the evaluation of HbA1c is not a sensitive endpoint and therefore efficacy studies evaluating HbA1c are not requested (EMEA/CHMP/BMWP/32775/2005_Rev.",1,purpose clinical biosimilarity exercise biosimilar insulin products evaluation sensitive endpoint therefore efficacy studies evaluating requested emea chmp bmwp,purpos clinic biosimilar exercis biosimilar insulin product evalu sensit endpoint therefor efficaci studi evalu request emea chmp bmwp
65,"1).Nevertheless, the applicant has conducted two large efficacy and safety (phase III) non-inferiority studies comparing the test and reference products in order to investigate how PK/PD features of the biosimilar candidate product translate into clinical parameters relevant for the management of patients with Type 1 and 2 DM.",1,applicant conducted two large efficacy safety phase iii non inferiority studies comparing test reference products order investigate pk pd features biosimilar candidate product translate clinical parameters relevant management patients type dm,applic conduct two larg efficaci safeti phase iii non inferior studi compar test refer product order investig pk pd featur biosimilar candid product translat clinic paramet relev manag patient type dm
66,This data is considered supportive in establishing biosimilarity.,0,data considered supportive establishing biosimilarity,data consid support establish biosimilar
67,"Both studies, demonstrated that SAR342434 is non-inferior to Humalog in improvement of glycaemic control by Week 26 and therefore provided strong supportive evidence about the comparability/ biosimilarity of the two products.",0,studies demonstrated non inferior humalog improvement glycaemic control week therefore provided strong supportive evidence comparability biosimilarity two products,studi demonstr non inferior humalog improv glycaem control week therefor provid strong support evid compar biosimilar two product
68,The 12-month results of study EFC12619 further supported similar clinical efficacy of SAR342434 and Humalog in T1DM subjects.,0,month results study supported similar clinical efficacy humalog subjects,month result studi support similar clinic efficaci humalog subject
69,The size of the safety database and duration of exposure is considered appropriate for the evaluation of the general safety profile of Insulin lispro Sanofi.,0,size safety database duration exposure considered appropriate evaluation general safety profile insulin lispro sanofi,size safeti databas durat exposur consid appropri evalu gener safeti profil insulin lispro sanofi
70,Safety and tolerability of Insulin lispro Sanofi and Humalog seem to be comparable and thus support biosimilarity of these two products.,0,safety tolerability insulin lispro sanofi humalog seem comparable thus support biosimilarity two products,safeti toler insulin lispro sanofi humalog seem compar thu support biosimilar two product
71,"With regard to immunogenicity, the differences in the AIA response between SARS342434 and Humalog were small and inconsistent.",2,regard immunogenicity differences aia response humalog small inconsistent,regard immunogen differ aia respons humalog small inconsist
72,Treatment-emergent AIA did not affect efficacy or safety endpoints in either T1DM or T2DM subjects.,0,treatment emergent aia affect efficacy safety endpoints either subjects,treatment emerg aia affect efficaci safeti endpoint either subject
73,"In conclusion, the safety profile of Insulin lispro Sanofi is acceptable and not different to that of Humalog.",0,conclusion safety profile insulin lispro sanofi acceptable different humalog,conclus safeti profil insulin lispro sanofi accept differ humalog
74,"The bioequivalence of the applied product Ivabradine, film-coated tablets, 7.5 mg with the respective strength of the reference product Procoralan film-coated tablets of Les Laboratoires Servier has been demonstrated in one bioequivalence study (study 14-VIN-785).",0,bioequivalence applied product ivabradine film coated tablets mg respective strength reference product procoralan film coated tablets les laboratoires servier demonstrated one bioequivalence study study vin,bioequival appli product ivabradin film coat tablet mg respect strength refer product procoralan film coat tablet le laboratoir servier demonstr one bioequival studi studi vin
75,"The study has been performed under fed conditions, which reflects recommendations in the brand leader’s SPC for the administration of the product.",0,study performed fed conditions reflects recommendations brand leaders spc administration product,studi perform fed condit reflect recommend brand leader spc administr product
76,The sample size was calculated to provide adequate power of bioequivalence analysis.,0,sample size calculated provide adequate power bioequivalence analysis,sampl size calcul provid adequ power bioequival analysi
77,The statistical methodology used in the studies is justified and consistent with the principles of guidelines on the investigation of bioequivalence.,0,statistical methodology used studies justified consistent principles guidelines investigation bioequivalence,statist methodolog use studi justifi consist principl guidelin investig bioequival
78,In accordance with the study protocol the study meets the bioequivalence criteria as 90% confidence intervals for the ln-transformed pharmacokinetic parameters Cmax and AUC0-t for ivabradine is within the acceptance range of 80.00% - 125.00% with power (1-β) 99.45 and 99.99 respectively.,0,accordance study protocol study meets bioequivalence criteria confidence intervals ln transformed pharmacokinetic parameters cmax ivabradine within acceptance range power β respectively,accord studi protocol studi meet bioequival criteria confid interv ln transform pharmacokinet paramet cmax ivabradin within accept rang power β respect
79,The bioequivalence study appears to have been well conducted.,0,bioequivalence study appears well conducted,bioequival studi appear well conduct
80,"An acceptable justification for a biowaiver of Ivabradine Hydrochloride, 5 mg, film-coated tablets has been provided.",0,acceptable justification biowaiver ivabradine hydrochloride mg film coated tablets provided,accept justif biowaiv ivabradin hydrochlorid mg film coat tablet provid
81,"to the EMA Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **), Ivabradine 5 mg film-coated tablets satisfy the conditions for waiver of bioequivalence studies conducted on the applied product 7.5 mg strength.",0,ema guideline investigation bioequivalence cpmp ewp qwp rev corr ivabradine mg film coated tablets satisfy conditions waiver bioequivalence studies conducted applied product mg strength,ema guidelin investig bioequival cpmp ewp qwp rev corr ivabradin mg film coat tablet satisfi condit waiver bioequival studi conduct appli product mg strength
82,"The efficacy data of the two phase 3 placebo-controlled studies in patients who received background DMARDs showed that both dose regimens of sarilumab (150 mg q2w, 200 mg q2w) were superior to placebo regarding improvement of signs and symptoms (ACR20 responses), of physical function (change from baseline in HAQ-DI) and of progression in structural damage (mTSS, only study EFC11072).",0,efficacy data two phase placebo controlled studies patients received background dmards showed dose regimens sarilumab mg mg superior placebo regarding improvement signs symptoms responses physical function change baseline haq di progression structural damage mtss study,efficaci data two phase placebo control studi patient receiv background dmard show dose regimen sarilumab mg mg superior placebo regard improv sign symptom respons physic function chang baselin haq di progress structur damag mtss studi
83,The active-comparator study demonstrated the efficacy of sarilumab as monotherapy and relative to the biologic DMARD adalimumab.,0,active comparator study demonstrated efficacy sarilumab monotherapy relative biologic dmard adalimumab,activ compar studi demonstr efficaci sarilumab monotherapi rel biolog dmard adalimumab
84,"Overall, data of the submitted studies are considered overall adequate to identify the patient population of the indication.",0,overall data submitted studies considered overall adequate identify patient population indication,overal data submit studi consid overal adequ identifi patient popul indic
85,The safety observation is based on a total of 3354 patients exposed to at least 1 dose of sarilumab for a total of 5981.0 patient-years of exposure.,1,safety observation based total patients exposed least dose sarilumab total patient years exposure,safeti observ base total patient expos least dose sarilumab total patient year exposur
86,"Sarilumab is associated with infections (including serious infections), decrease in ANC and platelet count, and increase in ALT and lipids, all of which are events consistent with the known effect of IL-6 inhibition, and with injection site reactions, consistent with a SC route of administration.",1,sarilumab associated infections including serious infections decrease anc platelet count increase alt lipids events consistent known effect il inhibition injection site reactions consistent sc route administration,sarilumab associ infect includ seriou infect decreas anc platelet count increas alt lipid event consist known effect il inhibit inject site reaction consist sc rout administr
87,No new safety concerns were identified during the development program in the clinical trial population.,0,new safety concerns identified development program clinical trial population,new safeti concern identifi develop program clinic trial popul
88,The efficacy of the combination of lenvatinib with everolimus has been shown.,0,efficacy combination lenvatinib everolimus shown,efficaci combin lenvatinib everolimu shown
89,Lenvatinib/everolimus combination therapy demonstrated improved PFS compared to everolimus monotherapy with a median PFS of 14.6 months vs. 5.5 months.,0,lenvatinib everolimus combination therapy demonstrated improved pfs compared everolimus monotherapy median pfs months vs months,lenvatinib everolimu combin therapi demonstr improv pf compar everolimu monotherapi median pf month vs month
90,Additional sensitivity analyses performed confirmed the robustness of observed PFS.,0,additional sensitivity analyses performed confirmed robustness observed pfs,addit sensit analys perform confirm robust observ pf
91,"Furthermore, encouraging signs of a prolonged OS were seen in patients treated with the combination of lenvatinib and everolimus combination therapy as per the primary analysis as well as the two updated analyses that span a more than 1-year period.",0,furthermore encouraging signs prolonged os seen patients treated combination lenvatinib everolimus combination therapy per primary analysis well two updated analyses span year period,furthermor encourag sign prolong os seen patient treat combin lenvatinib everolimu combin therapi per primari analysi well two updat analys span year period
92,A similar trend towards prolonged OS was also observed in favour of lenvatinib monotherapy but less obvious than with combination therapy.,0,similar trend towards prolonged os also observed favour lenvatinib monotherapy less obvious combination therapy,similar trend toward prolong os also observ favour lenvatinib monotherapi less obviou combin therapi
93,The overall safety profile of lenvatinib-everolimus combination is consistent with known safety profiles of its components observed either in other indications (for lenvatinib) or in the intended indication (for everolimus).,0,overall safety profile lenvatinib everolimus combination consistent known safety profiles components observed either indications lenvatinib intended indication everolimus,overal safeti profil lenvatinib everolimu combin consist known safeti profil compon observ either indic lenvatinib intend indic everolimu
94,The reported toxicity was in general predictable and manageable.,0,reported toxicity general predictable manageable,report toxic gener predict manag
95,No new safety signal has been reported.,0,new safety signal reported,new safeti signal report
96,"However, most of these adverse events were well managed by dose reduction, interruption or by additional medical treatment.",0,however adverse events well managed dose reduction interruption additional medical treatment,howev advers event well manag dose reduct interrupt addit medic treatment
97,"However, precaution is warranted given a small size of safety database, a limited information on long-term toxicity, and a limited data on PK/PD interactions together with indication on potential for worsening toxicity for VEGFRi -mTOR inhibitor combinations in general.",2,however precaution warranted given small size safety database limited information long term toxicity limited data pk pd interactions together indication potential worsening toxicity vegfri mtor inhibitor combinations general,howev precaut warrant given small size safeti databas limit inform long term toxic limit data pk pd interact togeth indic potenti worsen toxic vegfri mtor inhibitor combin gener
98,"Although toxicity appears to be manageable with the intended combination, an onset of more frequent or severe toxicity may occur in a larger database and/or at longer term.",2,although toxicity appears manageable intended combination onset frequent severe toxicity may occur larger database longer term,although toxic appear manag intend combin onset frequent sever toxic may occur larger databas longer term
99,Poor tolerability of the combination is manifest with high rates of discontinuations due to AEs and dose modifications.,2,poor tolerability combination manifest high rates discontinuations due aes dose modifications,poor toler combin manifest high rate discontinu due ae dose modif
100,"Therefore, further studies need to be conducted in relevant clinical setting in order to provide comprehensive data and to improve tolerability profile of the combination in view of a limited safety database for the combination treatment at intended doses/schedule, related uncertainties and poor tolerability of the combination (high rate of treatment discontinuation and dose modifications).",2,therefore studies need conducted relevant clinical setting order provide comprehensive data improve tolerability profile combination view limited safety database combination treatment intended doses schedule related uncertainties poor tolerability combination high rate treatment discontinuation dose modifications,therefor studi need conduct relev clinic set order provid comprehens data improv toler profil combin view limit safeti databas combin treatment intend dose schedul relat uncertainti poor toler combin high rate treatment discontinu dose modif
101,The CHMP considers the following measures necessary to address issues related to safety,2,chmp considers following measures necessary address issues related safety,chmp consid follow measur necessari address issu relat safeti
102,Study 307 is requested to further characterise the safety and tolerability profile of the combination therapy and further contribute to knowledge on PK and PK/PD of lenvatinib and everolimus and their PK and PD interactions.,2,study requested characterise safety tolerability profile combination therapy contribute knowledge pk pk pd lenvatinib everolimus pk pd interactions,studi request characteris safeti toler profil combin therapi contribut knowledg pk pk pd lenvatinib everolimu pk pd interact
103,Study 221 will continue to characterize safety for the combination treatment in patients with non clear cell renal carcinoma.,1,study continue characterize safety combination treatment patients non clear cell renal carcinoma,studi continu character safeti combin treatment patient non clear cell renal carcinoma
104,"Study 010 will assess in vitro lenvatinib protein binding, determine the unbound drug concentrations in order to define correctly the dose-adjustment in patients with severe hepatic and renal impairment.",1,study assess vitro lenvatinib protein binding determine unbound drug concentrations order define correctly dose adjustment patients severe hepatic renal impairment,studi assess vitro lenvatinib protein bind determin unbound drug concentr order defin correctli dose adjust patient sever hepat renal impair
105,Studies requested for Lenvima will also provide relevant safety information for this application,2,studies requested lenvima also provide relevant safety information application,studi request lenvima also provid relev safeti inform applic
106,"Based on the available data, the CHMP considered that all criteria for a BCS-based biowaiver were met. ",0,based available data chmp considered criteria bcs based biowaiver met,base avail data chmp consid criteria bc base biowaiv met
107,"Therefore the absence of a bioequivalence study was considered justified and the CHMP concluded that no clinical data were needed to support the application for Lacosamide Accord 50 mg, 100 mg, 150 mg and 200 mg film-coated tablets as a generic medicinal product to Vimpat.",0,therefore absence bioequivalence study considered justified chmp concluded clinical data needed support application lacosamide accord mg mg mg mg film coated tablets generic medicinal product vimpat,therefor absenc bioequival studi consid justifi chmp conclud clinic data need support applic lacosamid accord mg mg mg mg film coat tablet gener medicin product vimpat
108,"Overall, the available clinical efficacy data were considered adequate to support the use of cladribine in the treatment of adult patients with highly active RMS as defined by clinical or imaging features.",0,overall available clinical efficacy data considered adequate support use cladribine treatment adult patients highly active rms defined clinical imaging features,overal avail clinic efficaci data consid adequ support use cladribin treatment adult patient highli activ rm defin clinic imag featur
109,Results from the pivotal study CLARITY showed a clinically relevant effect of cladribine in patients with RMS in terms of reduction of relapse rate as well as MRI lesions and delay in disability progression.,0,results pivotal study clarity showed clinically relevant effect cladribine patients rms terms reduction relapse rate well mri lesions delay disability progression,result pivot studi clariti show clinic relev effect cladribin patient rm term reduct relaps rate well mri lesion delay disabl progress
110,Subgroup analyses suggested a larger effect size in patients with high disease activity.,1,subgroup analyses suggested larger effect size patients high disease activity,subgroup analys suggest larger effect size patient high diseas activ
111,"Furthermore, data in SPMS patients with superimposed relapses, although very limited, supported a beneficial effect of cladribine on the relapse rate in this population.",0,furthermore data spms patients superimposed relapses although limited supported beneficial effect cladribine relapse rate population,furthermor data spm patient superimpos relaps although limit support benefici effect cladribin relaps rate popul
112,"Based on these data and since relapses in both SPMS and RRMS patients have the same underlying inflammatory pathophysiology, patients with RMS (instead of RRMS) were considered a more suitable target population.",2,based data since relapses spms rrms patients underlying inflammatory pathophysiology patients rms instead rrms considered suitable target population,base data sinc relaps spm rrm patient underli inflammatori pathophysiolog patient rm instead rrm consid suitabl target popul
113,The data furthermore support the use of a cumulative dose of 3.5 mg/kg to be administered in 2 courses each for 2 years.,0,data furthermore support use cumulative dose mg kg administered courses years,data furthermor support use cumul dose mg kg administ cours year
114,Maintenance of the treatment effect in year 3 and 4 was supported by long-term data from CLARITY EXT.,0,maintenance treatment effect year supported long term data clarity ext,mainten treatment effect year support long term data clariti ext
115,No clinically relevant added benefit of additional treatment cycles beyond year 2 was evident.,1,clinically relevant added benefit additional treatment cycles beyond year evident,clinic relev ad benefit addit treatment cycl beyond year evid
116,"Overall, the CHMP was of the view that the available clinical safety data were adequate for the purpose of assessing the safety of cladribine for the use as treatment of adult patients with highly active RMS.",0,overall chmp view available clinical safety data adequate purpose assessing safety cladribine use treatment adult patients highly active rms,overal chmp view avail clinic safeti data adequ purpos assess safeti cladribin use treatment adult patient highli activ rm
117,"The main safety issues were related to the risks of prolonged severe lymphopenia, infections including reactivation of latent infections and opportunistic infections as well as malignancies.",1,main safety issues related risks prolonged severe lymphopenia infections including reactivation latent infections opportunistic infections well malignancies,main safeti issu relat risk prolong sever lymphopenia infect includ reactiv latent infect opportunist infect well malign
118,"For the latter, uncertainties due to the observed imbalance of cases occurring in patients treated with cladribine compared to placebo as well as the low number of events remained, although supportive analyses did not support a causal association.",1,latter uncertainties due observed imbalance cases occurring patients treated cladribine compared placebo well low number events remained although supportive analyses support causal association,latter uncertainti due observ imbal case occur patient treat cladribin compar placebo well low number event remain although support analys support causal associ
119,"Overall, the risk minimisation measures including the safety information in the product information as well as the prescriber and patient guide were considered adequate to address the risks with cladribine treatment, while further data are gathered in the post-marketing setting",0,overall risk minimisation measures including safety information product information well prescriber patient guide considered adequate address risks cladribine treatment data gathered post marketing setting,overal risk minimis measur includ safeti inform product inform well prescrib patient guid consid adequ address risk cladribin treatment data gather post market set
120,Of particular interest this FDC comprises two pangenotypic components with high potency and high genetic barrier.,1,particular interest fdc comprises two pangenotypic components high potency high genetic barrier,particular interest fdc compris two pangenotyp compon high potenc high genet barrier
121,In the HCV GT1-infected population (the most widely represented in the EU) the observed results -with 99% SVR12 achieved with a convenient 8 weeks treatment duration in non-cirrhotic TN or TE-PRS patients and 97% in cirrhotic patients with a 12 weeks treatment duration- support the fact that this FDC will represent an optimization in the therapeutic armamentarium. ,0,hcv infected population widely represented eu observed results achieved convenient weeks treatment duration non cirrhotic tn te prs patients cirrhotic patients weeks treatment duration support fact fdc represent optimization therapeutic armamentarium,hcv infect popul wide repres eu observ result achiev conveni week treatment durat non cirrhot tn te pr patient cirrhot patient week treatment durat support fact fdc repres optim therapeut armamentarium
122,"As part of the response to CHMP questions throughout the assessment, some clarifications and some additional data from ongoing studies (EXPEDITION-2 notably) were provided by the applicant in support of the efficacy of the product.",1,part response chmp questions throughout assessment clarifications additional data ongoing studies expedition notably provided applicant support efficacy product,part respons chmp question throughout assess clarif addit data ongo studi expedit notabl provid applic support efficaci product
123,"CHMP thus acknowledged that the applicant’s proposal for a treatment recommendation could overall be followed in DAA treatment naïve patients, having in mind the possibility of bridging efficacy from GT1 based on comparable in vitro activity leading to favour a simplified regimen for a programmatic approach to HCV eradication (targeted by 2030 by WHO).",0,chmp thus acknowledged applicants proposal treatment recommendation could overall followed daa treatment naïve patients mind possibility bridging efficacy based comparable vitro activity leading favour simplified regimen programmatic approach hcv eradication targeted,chmp thu acknowledg applic propos treatment recommend could overal follow daa treatment naïv patient mind possibl bridg efficaci base compar vitro activ lead favour simplifi regimen programmat approach hcv erad target
124,"Nevertheless, CHMP noted that since the clinical development has been built mainly to promote the use of this dual therapy in first line treatment rather than in retreatment, the limited sample sized MAGELLAN-1 study (without GT3 patients) in DAA TE leaves many uncertainties for the use of this dual therapy in patients failing DAA.",2,nevertheless chmp noted since clinical development built mainly promote use dual therapy first line treatment rather retreatment limited sample sized magellan study without patients daa te leaves many uncertainties use dual therapy patients failing daa,nevertheless chmp note sinc clinic develop built mainli promot use dual therapi first line treatment rather retreat limit sampl size magellan studi without patient daa te leav mani uncertainti use dual therapi patient fail daa
125,The safety profile of Maviret (glecaprevir/pibrentasvir) is favourable with no major concern identified.,0,safety profile maviret glecaprevir pibrentasvir favourable major concern identified,safeti profil maviret glecaprevir pibrentasvir favour major concern identifi
126,"While the risk of ALT elevations seems lower as compared to previously authorized NS3/4A, it remains that some situations (namely in case of combination with EE-based regimens) have been identified at increased hepatic risk.",1,risk alt elevations seems lower compared previously authorized remains situations namely case combination ee based regimens identified increased hepatic risk,risk alt elev seem lower compar previous author remain situat name case combin ee base regimen identifi increas hepat risk
127,This has been appropriately covered in the Maviret SmPC by the addition of a contra-indication with EE-containing medicines.,0,appropriately covered maviret smpc addition contra indication ee containing medicines,appropri cover maviret smpc addit contra indic ee contain medicin
128,"To support the application, the applicant has submitted one bioequivalence study.",1,support application applicant submitted one bioequivalence study,support applic applic submit one bioequival studi
129,"It was a randomized, blind, 1-way parallel bioequivalence study of nitisinone 10 mg capsule and Orfadin (reference) following a 10 mg dose in healthy subjects under fasting conditions.",1,randomized blind way parallel bioequivalence study nitisinone mg capsule orfadin reference following mg dose healthy subjects fasting conditions,random blind way parallel bioequival studi nitisinon mg capsul orfadin refer follow mg dose healthi subject fast condit
130,The concerns raised during the procedure regarding the BE have been satisfactorily answered and the product is approvable from the clinical point of view.,0,concerns raised procedure regarding satisfactorily answered product approvable clinical point view,concern rais procedur regard satisfactorili answer product approv clinic point view
131,No additional clinical studies were provided within current application.,1,additional clinical studies provided within current application,addit clinic studi provid within current applic
132,A clinical overview has been provided and was based on up-to-date and adequate scientific literature.,1,clinical overview provided based date adequate scientific literature,clinic overview provid base date adequ scientif literatur
133,The CHMP considered this application acceptable from clinical point of view.,0,chmp considered application acceptable clinical point view,chmp consid applic accept clinic point view
134,A summary of the literature with regard to clinical data of Pemetrexed Hospira UK Limited and justifications that the different salt of the active substance does not differ significantly in properties with regards to safety and efficacy of the reference product was provided and was accepted by the CHMP. ,0,summary literature regard clinical data pemetrexed hospira uk limited justifications different salt active substance differ significantly properties regards safety efficacy reference product provided accepted chmp,summari literatur regard clinic data pemetrex hospira uk limit justif differ salt activ substanc differ significantli properti regard safeti efficaci refer product provid accept chmp
135,This is in accordance with the relevant guideline and additional clinical studies were not considered necessary.,0,accordance relevant guideline additional clinical studies considered necessary,accord relev guidelin addit clinic studi consid necessari
136,A single dose bioequivalence study was considered sufficient since the application concerns an immediate release formulation.,0,single dose bioequivalence study considered sufficient since application concerns immediate release formulation,singl dose bioequival studi consid suffici sinc applic concern immedi releas formul
137,Biosimilarity of CT-P10 and MabThera is considered demonstrated based on the efficacy data.,0,biosimilarity ct mabthera considered demonstrated based efficacy data,biosimilar ct mabthera consid demonstr base efficaci data
138,"In the pivotal RA trial, efficacy results in terms of DAS28 and ACR were shown to be comparable between CT-P10 and MabThera.",0,pivotal ra trial efficacy results terms acr shown comparable ct mabthera,pivot ra trial efficaci result term acr shown compar ct mabthera
139,"In addition, PK data discussed support the extrapolation to the autoimmune indications MPA/GPA.",0,addition pk data discussed support extrapolation autoimmune indications mpa gpa,addit pk data discuss support extrapol autoimmun indic mpa gpa
140,"The objectives of study CT-P10 3.3 were to demonstrate similarity in pharmacokinetics and non-inferiority in efficacy of CT-P10 to Rituxan as primary endpoints when coadministered with CVP in patients with advanced FL; these objectives have been met and furthermore, extrapolation in the context of NHL and CLL indications is acceptable.",0,objectives study ct demonstrate similarity pharmacokinetics non inferiority efficacy ct rituxan primary endpoints coadministered cvp patients advanced fl objectives met furthermore extrapolation context nhl cll indications acceptable,object studi ct demonstr similar pharmacokinet non inferior efficaci ct rituxan primari endpoint coadminist cvp patient advanc fl object met furthermor extrapol context nhl cll indic accept
141,The overall safety profile of CT-P10 appeared roughly similar to that of the reference product although the pooled incidences of AEs and SAEs were generally lower for the reference products.,1,overall safety profile ct appeared roughly similar reference product although pooled incidences aes saes generally lower reference products,overal safeti profil ct appear roughli similar refer product although pool incid ae sae gener lower refer product
142,"Therefore, the available safety data are considered supportive of biosimilarity between CT-P10 and MabThera.",0,therefore available safety data considered supportive biosimilarity ct mabthera,therefor avail safeti data consid support biosimilar ct mabthera
143,"Most common reported events were infections, infusion related reactions.",1,common reported events infections infusion related reactions,common report event infect infus relat reaction
144,The frequencies and nature of the adverse events were in line with those reported for the innovator MabThera/Rituxan in the RA and NLH study populations.,0,frequencies nature adverse events line reported innovator mabthera rituxan ra nlh study populations,frequenc natur advers event line report innov mabthera rituxan ra nlh studi popul
145,"Although dataset of AFL patients has been updated, data are still considered very limited to reach firm conclusion about safety proflie.",2,although dataset afl patients updated data still considered limited reach firm conclusion safety proflie,although dataset afl patient updat data still consid limit reach firm conclus safeti profli
146,Additional safety data from Maintenance Study Period CT-P10 3.3.and Follow-up Period should be provided (see RMP).,2,additional safety data maintenance study period ct follow period provided see rmp,addit safeti data mainten studi period ct follow period provid see rmp
147,The planned extension studies CT-P10 3.2 (RA) CT-P10 3.3 (AFL) and CT-P10 3.4 (LTBFL) listed in the RMP will provide additional long term safety data.,1,planned extension studies ct ra ct afl ct ltbfl listed rmp provide additional long term safety data,plan extens studi ct ra ct afl ct ltbfl list rmp provid addit long term safeti data
148,Biosimilarity of CT-P10 and MabThera is considered demonstrated based on the efficacy data.,0,biosimilarity ct mabthera considered demonstrated based efficacy data,biosimilar ct mabthera consid demonstr base efficaci data
149,"In the pivotal RA trial, efficacy results in terms of DAS28 and ACR were shown to be comparable between CT-P10 and MabThera.",0,pivotal ra trial efficacy results terms acr shown comparable ct mabthera,pivot ra trial efficaci result term acr shown compar ct mabthera
150,"In addition, PK data discussed support the extrapolation to the autoimmune indications MPA/GPA.",0,addition pk data discussed support extrapolation autoimmune indications mpa gpa,addit pk data discuss support extrapol autoimmun indic mpa gpa
151,"The objectives of study CT-P10 3.3 were to demonstrate similarity in pharmacokinetics and non-inferiority in efficacy of CT-P10 to Rituxan as primary endpoints when coadministered with CVP in patients with advanced FL; these objectives have been met and furthermore, extrapolation in the context of NHL and CLL indications is acceptable.",0,objectives study ct demonstrate similarity pharmacokinetics non inferiority efficacy ct rituxan primary endpoints coadministered cvp patients advanced fl objectives met furthermore extrapolation context nhl cll indications acceptable,object studi ct demonstr similar pharmacokinet non inferior efficaci ct rituxan primari endpoint coadminist cvp patient advanc fl object met furthermor extrapol context nhl cll indic accept
152,The overall safety profile of CT-P10 appeared roughly similar to that of the reference product although the pooled incidences of AEs and SAEs were generally lower for the reference products.,1,overall safety profile ct appeared roughly similar reference product although pooled incidences aes saes generally lower reference products,overal safeti profil ct appear roughli similar refer product although pool incid ae sae gener lower refer product
153,"Therefore, the available safety data are considered supportive of biosimilarity between CT-P10 and MabThera.",0,therefore available safety data considered supportive biosimilarity ct mabthera,therefor avail safeti data consid support biosimilar ct mabthera
154,"Most common reported events were infections, infusion related reactions.",1,common reported events infections infusion related reactions,common report event infect infus relat reaction
155,The frequencies and nature of the adverse events were in line with those reported for the innovator MabThera/Rituxan in the RA and NLH study populations.,0,frequencies nature adverse events line reported innovator mabthera rituxan ra nlh study populations,frequenc natur advers event line report innov mabthera rituxan ra nlh studi popul
156,"Although dataset of AFL patients has been updated, data are still considered very limited to reach firm conclusion about safety proflie.",2,although dataset afl patients updated data still considered limited reach firm conclusion safety proflie,although dataset afl patient updat data still consid limit reach firm conclus safeti profli
157,Additional safety data from Maintenance Study Period CT-P10 3.3. and Follow-up Period should be provided (see RMP).,2,additional safety data maintenance study period ct follow period provided see rmp,addit safeti data mainten studi period ct follow period provid see rmp
158,The planned extension studies CT-P10 3.2 (RA) CT-P10 3.3 (AFL) and CT-P10 3.4 (LTBFL) listed in the RMP will provide additional long term safety data.,1,planned extension studies ct ra ct afl ct ltbfl listed rmp provide additional long term safety data,plan extens studi ct ra ct afl ct ltbfl list rmp provid addit long term safeti data
159,The results presented on efficacy support the biosimilarity claim between the test product SB5 and the reference product EU Humira.,0,results presented efficacy support biosimilarity claim test product reference product eu humira,result present efficaci support biosimilar claim test product refer product eu humira
160,The number of subjects is sufficient for comparing the safety profile of the biosimilar candidate SB5 and reference medicinal product EU-Humira and studying the safety of a biosimilar product for up to one year.,0,number subjects sufficient comparing safety profile biosimilar candidate reference medicinal product eu humira studying safety biosimilar product one year,number subject suffici compar safeti profil biosimilar candid refer medicin product eu humira studi safeti biosimilar product one year
161,"Broadly, the number, severity and type of TEAEs, SAEs, AEs of special interest, treatment discontinuations due to AEs, laboratory findings were comparable between SB5 and Humira and mirroring the safety profile as described in the SmPC of Humira.",0,broadly number severity type teaes saes aes special interest treatment discontinuations due aes laboratory findings comparable humira mirroring safety profile described smpc humira,broadli number sever type teae sae ae special interest treatment discontinu due ae laboratori find compar humira mirror safeti profil describ smpc humira
162,"The frequency of related AEs, severity of AEs and AESIs remained similar for the group who transitioned from Humira to SB5 at week 24.",0,frequency related aes severity aes aesis remained similar group transitioned humira week,frequenc relat ae sever ae aesi remain similar group transit humira week
163,"More detailed data on injection site reactions, hypersensitivity and anaphylactic reactions were requested in order to allow a thorough assessment of this issue both in subjects with and without ADAs.",2,detailed data injection site reactions hypersensitivity anaphylactic reactions requested order allow thorough assessment issue subjects without adas,detail data inject site reaction hypersensit anaphylact reaction request order allow thorough assess issu subject without ada
164,The submitted additional analyses further support the comparability of the safety profile of SB5 and Humira.,0,submitted additional analyses support comparability safety profile humira,submit addit analys support compar safeti profil humira
165,"With regard to immunogenicity, the incidence and titre distribution of ADAs were compared and seemed similar for SB5 and Humira, with about half of all subjects developing neutralising antibodies in each treatment group.",0,regard immunogenicity incidence titre distribution adas compared seemed similar humira half subjects developing neutralising antibodies treatment group,regard immunogen incid titr distribut ada compar seem similar humira half subject develop neutralis antibodi treatment group
166,No worsening of the immunogenicity profile was observed after transitioning from Humira to SB5.,0,worsening immunogenicity profile observed transitioning humira,worsen immunogen profil observ transit humira
167,"Since Rolufta application is an informed consent of Incruse application, the clinical data in support of the Rolufta application are identical to the up-to-date clinical data of Incruse dossier, which have been assessed and authorised (including all post-marketing procedures).",0,since rolufta application informed consent incruse application clinical data support rolufta application identical date clinical data incruse dossier assessed authorised including post marketing procedures,sinc rolufta applic inform consent incrus applic clinic data support rolufta applic ident date clinic data incrus dossier assess authoris includ post market procedur
168,"Overall, ABP 501 has in the RA study shown similarity to adalimumab in several analyses.",0,overall abp ra study shown similarity adalimumab several analyses,overal abp ra studi shown similar adalimumab sever analys
169,"The primary endpoint was met, and similarity at week 24 was indicated with low point estimates and narrow CI intervals both for ACR20 RR and Risk Difference.",0,primary endpoint met similarity week indicated low point estimates narrow ci intervals rr risk difference,primari endpoint met similar week indic low point estim narrow ci interv rr risk differ
170,Also mean change in DAS28-CRP showed high similarity at all visits.,0,also mean change crp showed high similarity visits,also mean chang crp show high similar visit
171,"ACR20 results per visit showed significant differences which may be interpreted as indicating a faster onset of effect for ABP 501, which could question similarity.",2,results per visit showed significant differences may interpreted indicating faster onset effect abp could question similarity,result per visit show signific differ may interpret indic faster onset effect abp could question similar
172,"However, these results are not seen for DAS28 which is favourable, or for ACR50 or ACR70, and as such it is concluded, that the difference seen at week 2 in ACR20 is likely to be a chance finding rather than a true difference.",0,however results seen favourable concluded difference seen week likely chance finding rather true difference,howev result seen favour conclud differ seen week like chanc find rather true differ
173,"Also the psoriasis study met the primary endpoint with a point estimate of difference of 2% with narrow CIs, indicating similarity.",0,also psoriasis study met primary endpoint point estimate difference narrow cis indicating similarity,also psoriasi studi met primari endpoint point estim differ narrow ci indic similar
174,The secondary endpoints PASI 75 and sPGA showed point estimates of 7% difference with a wide CI.,1,secondary endpoints pasi spga showed point estimates difference wide ci,secondari endpoint pasi spga show point estim differ wide ci
175,"Overall, clinical similarity between ABP 501 and adalimumab has been demonstrated.",0,overall clinical similarity abp adalimumab demonstrated,overal clinic similar abp adalimumab demonstr
176,The safety profile of ABP 501 and Humira is considered comparable.,0,safety profile abp humira considered comparable,safeti profil abp humira consid compar
177,"The majority of treated infants with infantile-onset SMA achieved improvement, with a great proportion reaching a clinically meaningful and continued improvements in motor milestones (e.g. independent sitting, standing and walking), muscle strength, and motor function that exceed those of the sham control-treated infants in Study CS3B and the natural history of the disease, where a progressive loss of motor function is observed",0,majority treated infants infantile onset sma achieved improvement great proportion reaching clinically meaningful continued improvements motor milestones eg independent sitting standing walking muscle strength motor function exceed sham control treated infants study natural history disease progressive loss motor function observed,major treat infant infantil onset sma achiev improv great proport reach clinic meaning continu improv motor mileston eg independ sit stand walk muscl strength motor function exceed sham control treat infant studi natur histori diseas progress loss motor function observ
178,Data from treated pre-symptomatic infants with genetically confirmed SMA show that they are achieving motor milestones and developing muscle strength and motor function with the nusinersen treatment that are more consistent with those of normal infants than symptomatic infants with SMA,0,data treated pre symptomatic infants genetically confirmed sma show achieving motor milestones developing muscle strength motor function nusinersen treatment consistent normal infants symptomatic infants sma,data treat pre symptomat infant genet confirm sma show achiev motor mileston develop muscl strength motor function nusinersen treatment consist normal infant symptomat infant sma
179,Subjects with later-onset SMA who received nusinersen achieved and maintained motor function across multiple measures and milestones such as the ability to walk that are completely inconsistent with natural history,0,subjects later onset sma received nusinersen achieved maintained motor function across multiple measures milestones ability walk completely inconsistent natural history,subject later onset sma receiv nusinersen achiev maintain motor function across multipl measur mileston abil walk complet inconsist natur histori
180,"The difference in magnitude across endpoints is in alignment with the understanding of the pathology of SMA, where deficiency in SMN protein leads to disease progression from events more proximal to the action of SMN such as declines in motor neuron health as measured by CMAP and CHOP INTEND, through those that are more distal, as measured by motor milestones and event-free survival",1,difference magnitude across endpoints alignment understanding pathology sma deficiency smn protein leads disease progression events proximal action smn declines motor neuron health measured cmap chop intend distal measured motor milestones event free survival,differ magnitud across endpoint align understand patholog sma defici smn protein lead diseas progress event proxim action smn declin motor neuron health measur cmap chop intend distal measur motor mileston event free surviv
181,Data from the ongoing studies in infantile-onset SMA support that treatment with nusinersen has the potential to prolong overall and event-free survival,0,data ongoing studies infantile onset sma support treatment nusinersen potential prolong overall event free survival,data ongo studi infantil onset sma support treatment nusinersen potenti prolong overal event free surviv
182,"They also support the need for early treatment with nusinersen, since shortly after the loading phase was complete, the rate of ventilation among nusinersen-treated subjects separated from that of the controls",0,also support need early treatment nusinersen since shortly loading phase complete rate ventilation among nusinersen treated subjects separated controls,also support need earli treatment nusinersen sinc shortli load phase complet rate ventil among nusinersen treat subject separ control
183,"Taken together, these data demonstrate consistently that nusinersen has produced meaningful benefits across a broad range of SMA phenotypes",0,taken together data demonstrate consistently nusinersen produced meaningful benefits across broad range sma phenotypes,taken togeth data demonstr consist nusinersen produc meaning benefit across broad rang sma phenotyp
184,"The consistency among the various key clinically meaningful endpoints, each of which provide independent measures central to the pathology of SMA, support significant efficacy in both pre-symptomatic and symptomatic subjects and across infantile-onset and later-onset SMA",0,consistency among various key clinically meaningful endpoints provide independent measures central pathology sma support significant efficacy pre symptomatic symptomatic subjects across infantile onset later onset sma,consist among variou key clinic meaning endpoint provid independ measur central patholog sma support signific efficaci pre symptomat symptomat subject across infantil onset later onset sma
185,"The current studies do not provide evidence that the treatment effects persist with indefinite length of treatment, neither in infantile nor in later onset SMA",2,current studies provide evidence treatment effects persist indefinite length treatment neither infantile later onset sma,current studi provid evid treatment effect persist indefinit length treatment neither infantil later onset sma
186,The CHMP considers the following measures as key to the B/R ratio of the product and necessary to address issues related to efficacy:,2,chmp considers following measures key b r ratio product necessary address issues related efficacy,chmp consid follow measur key b r ratio product necessari address issu relat efficaci
187,"PAES: In order to evaluate the long term efficacy and safety of Nusinersen in symptomatic patients with spinal muscular atrophy, Phase 3, open-label extension study (SHINE, CS11)",2,paes order evaluate long term efficacy safety nusinersen symptomatic patients spinal muscular atrophy phase open label extension study shine,pae order evalu long term efficaci safeti nusinersen symptomat patient spinal muscular atrophi phase open label extens studi shine
188,the MAH should conduct and submit the results of the ,2,mah conduct submit results,mah conduct submit result
189,"• PAES: In order to evaluate the long term efficacy and safety of Nusinersen in pre-symptomatic patients with spinal muscular atrophy, the MAH should conduct and submit the results of the Phase 2, open-label study (NURTURE (SM201))",2,paes order evaluate long term efficacy safety nusinersen pre symptomatic patients spinal muscular atrophy mah conduct submit results phase open label study nurture,pae order evalu long term efficaci safeti nusinersen pre symptomat patient spinal muscular atrophi mah conduct submit result phase open label studi nurtur
190,"Along with the needed data on efficacy and safety to be derived from the above studies, their protocols include PK data collections",1,along needed data efficacy safety derived studies protocols include pk data collections,along need data efficaci safeti deriv studi protocol includ pk data collect
191,"These are being used to collect the required PK data in order to enable the company to make future decisions about whether any dose adjustment, or further investigation in to dose adjustment, is required",1,used collect required pk data order enable company make future decisions whether dose adjustment investigation dose adjustment required,use collect requir pk data order enabl compani make futur decis whether dose adjust investig dose adjust requir
192,CSF data are being collected from both these studies and will be used in the comprehensive update to the Pop PK model,1,csf data collected studies used comprehensive update pop pk model,csf data collect studi use comprehens updat pop pk model
193,"Additionally, the following measures will contribute to the better understanding of the efficacy, safety and clinical applicability of the product: ",1,additionally following measures contribute better understanding efficacy safety clinical applicability product,addit follow measur contribut better understand efficaci safeti clinic applic product
194,"• EMBRACE (SM202) - Phase 2, randomized, double-blind, sham- procedure controlled study to assess the safety, tolerability, PK, and efficacy in patients who were not eligible to participate in studies CS3b or CS4 ",1,embrace phase randomized double blind sham procedure controlled study assess safety tolerability pk efficacy patients eligible participate studies,embrac phase random doubl blind sham procedur control studi assess safeti toler pk efficaci patient elig particip studi
195,• Registries initiative - Collaborations with existing disease registries across the globe to capitalize on the available clinical experts and networks and modifying to be able to collect appropriate information and take in to account availability of medicinal product(s),1,registries initiative collaborations existing disease registries across globe capitalize available clinical experts networks modifying able collect appropriate information take account availability medicinal products,registri initi collabor exist diseas registri across globe capit avail clinic expert network modifi abl collect appropri inform take account avail medicin product
196,• Exploring higher doses - The company is requested to explore whether higher doses of nusinersen could show greater efficacy,1,exploring higher doses company requested explore whether higher doses nusinersen could show greater efficacy,explor higher dose compani request explor whether higher dose nusinersen could show greater efficaci
197,"The safety profile of nusinersen was characterized in subjects with infantile-onset SMA in a randomized controlled study and an open-label study; pre-symptomatic infants with SMA in an open-label study, and children with later-onset SMA in a randomized study and open-label studies",1,safety profile nusinersen characterized subjects infantile onset sma randomized controlled study open label study pre symptomatic infants sma open label study children later onset sma randomized study open label studies,safeti profil nusinersen character subject infantil onset sma random control studi open label studi pre symptomat infant sma open label studi children later onset sma random studi open label studi
198,Review of the available data demonstrated no safety concerns due to nusinersen exposure,0,review available data demonstrated safety concerns due nusinersen exposure,review avail data demonstr safeti concern due nusinersen exposur
199,The majority of AEs and SAEs reported in subjects exposed to nusinersen were consistent with the nature and frequency of events typically occurring in the context of SMA,0,majority aes saes reported subjects exposed nusinersen consistent nature frequency events typically occurring context sma,major ae sae report subject expos nusinersen consist natur frequenc event typic occur context sma
200,"Pre-symptomatic infants treated with nusinersen experienced fewer adverse events compared with symptomatic infants which is most likely due to their healthier baseline condition, which they maintained throughout participation in the study",1,pre symptomatic infants treated nusinersen experienced fewer adverse events compared symptomatic infants likely due healthier baseline condition maintained throughout participation study,pre symptomat infant treat nusinersen experienc fewer advers event compar symptomat infant like due healthier baselin condit maintain throughout particip studi
201,"In addition, the fatality rate in nusinersen-treated subjects with infantile-onset SMA was about half that of sham-controlled subjects",0,addition fatality rate nusinersen treated subjects infantile onset sma half sham controlled subjects,addit fatal rate nusinersen treat subject infantil onset sma half sham control subject
202,"nusinersen has demonstrated a favourable safety and efficacy pattern in the treatment of infantile-onset SMA from a randomized controlled clinical study, Study CS3B",0,nusinersen demonstrated favourable safety efficacy pattern treatment infantile onset sma randomized controlled clinical study study,nusinersen demonstr favour safeti efficaci pattern treatment infantil onset sma random control clinic studi studi
203,"This was supported by favourable safety and efficacy data from the interim analysis of a randomized controlled clinical study, CS4 in later-onset subjects, open-label studies in pre-symptomatic subjects, and subjects with infantile-onset and later-onset SMA, where the attainment of motor milestones in subjects receiving treatment differed from that seen in the natural history of SMA",0,supported favourable safety efficacy data interim analysis randomized controlled clinical study later onset subjects open label studies pre symptomatic subjects subjects infantile onset later onset sma attainment motor milestones subjects receiving treatment differed seen natural history sma,support favour safeti efficaci data interim analysi random control clinic studi later onset subject open label studi pre symptomat subject subject infantil onset later onset sma attain motor mileston subject receiv treatment differ seen natur histori sma
204,"Based on the totality of the data, it can be agreed that nusinersen has a positive benefit/risk profile for treating SMA",0,based totality data agreed nusinersen positive benefit risk profile treating sma,base total data agre nusinersen posit benefit risk profil treat sma
205,Long-term safety data will be obtained from the planned and ongoing studies.,1,long term safety data obtained planned ongoing studies,long term safeti data obtain plan ongo studi
206,The FRC has been investigated in a clinical programme of adequate design.,0,frc investigated clinical programme adequate design,frc investig clinic programm adequ design
207,The FRC is provided in two different pens with two different ratios between insulin glargine and lixisenatide which may increase the risk for medication errors.,2,frc provided two different pens two different ratios insulin glargine lixisenatide may increase risk medication errors,frc provid two differ pen two differ ratio insulin glargin lixisenatid may increas risk medic error
208,Study EFC12404 provides relevant information on the contribution of the mono-components to the effect of the FRC.,0,study provides relevant information contribution mono components effect frc,studi provid relev inform contribut mono compon effect frc
209,Insulin glargine primarily reduces HbA1c by decreasing the fasting plasma glucose whereas lixisenatide primarily reduces the post-prandial glucose excursion.,1,insulin glargine primarily reduces decreasing fasting plasma glucose whereas lixisenatide primarily reduces post prandial glucose excursion,insulin glargin primarili reduc decreas fast plasma glucos wherea lixisenatid primarili reduc post prandial glucos excurs
210,"The major contribution in HbA1c is due to insulin glargine as the treatment difference between the FRC and insulin glargine ranged from 0.3 % to 0.5 %, whereas the treatment difference between the FRC and lixisenatide was 0.8 %.",1,major contribution due insulin glargine treatment difference frc insulin glargine ranged whereas treatment difference frc lixisenatide,major contribut due insulin glargin treatment differ frc insulin glargin rang wherea treatment differ frc lixisenatid
211,"With the FRC, the decrease in HbA1c was achieved without increase in body weight, and without an increase in the reporting of hypoglycaemia compared to patients on monotherapy with insulin glargine.",0,frc decrease achieved without increase body weight without increase reporting hypoglycaemia compared patients monotherapy insulin glargine,frc decreas achiev without increas bodi weight without increas report hypoglycaemia compar patient monotherapi insulin glargin
212,"There was no difference in insulin dose with the FRC compared to monotherapy with insulin glargine in any of the studies, thus there was no insulin “saving” effect with the FRC when the insulin dose in the comparator group was capped at 60 U. ",1,difference insulin dose frc compared monotherapy insulin glargine studies thus insulin saving effect frc insulin dose comparator group capped u,differ insulin dose frc compar monotherapi insulin glargin studi thu insulin save effect frc insulin dose compar group cap u
213,The effect was consistent across studies and across investigated subgroups.,1,effect consistent across studies across investigated subgroups,effect consist across studi across investig subgroup
214,"In the studies, the FRC was always to be taken before breakfast, whereas the proposed SmPC states that Suliqua can be taken prior to any meal.",1,studies frc always taken breakfast whereas proposed smpc states suliqua taken prior meal,studi frc alway taken breakfast wherea propos smpc state suliqua taken prior meal
215,It is acknowledged that both insulin glargine and lixisenatide may be taken at any time of the day when used in mono-therapy.,1,acknowledged insulin glargine lixisenatide may taken time day used mono therapy,acknowledg insulin glargin lixisenatid may taken time day use mono therapi
216,"The recommendation has been further supported by data from the lixisenatide file, showing that no statistically significant differences are observed between pre-breakfast or pre-dinner dosing of lixisenatide.",1,recommendation supported data lixisenatide file showing statistically significant differences observed pre breakfast pre dinner dosing lixisenatide,recommend support data lixisenatid file show statist signific differ observ pre breakfast pre dinner dose lixisenatid
217,There is a lack of long-term data beyond 30 weeks with the FRC. ,2,lack long term data beyond weeks frc,lack long term data beyond week frc
218,"However, further analyses have shown that only a small proportion of patients (7% and 15%, study EFC12404 and EFC12405 respectively) had both reached the maximum dose and were in need of intensified treatment at week 30",0,however analyses shown small proportion patients study respectively reached maximum dose need intensified treatment week,howev analys shown small proport patient studi respect reach maximum dose need intensifi treatment week
219,"In addition, data from the lixisenatide file has been presented which shows maintenance of efficacy up to 76 weeks in combination with basal insulin.",0,addition data lixisenatide file presented shows maintenance efficacy weeks combination basal insulin,addit data lixisenatid file present show mainten efficaci week combin basal insulin
220,Thus it appears plausible that the effect can be maintained for a majority of patients at the doses,0,thus appears plausible effect maintained majority patients doses,thu appear plausibl effect maintain major patient dose
221,No new or unexpected adverse reactions were noted with the fixed combination of lixisenatide/insulin glargine (FRC) compared to the mono-components.,0,new unexpected adverse reactions noted fixed combination lixisenatide insulin glargine frc compared mono components,new unexpect advers reaction note fix combin lixisenatid insulin glargin frc compar mono compon
222,The adverse reaction patterns differed however in the aspect that the FRC group had a lower frequency of subjects with gastrointestinal adverse reactions compared to the lixisenatide group but a higher frequency of subjects with these reactions compared to use with insulin glargine.,1,adverse reaction patterns differed however aspect frc group lower frequency subjects gastrointestinal adverse reactions compared lixisenatide group higher frequency subjects reactions compared use insulin glargine,advers reaction pattern differ howev aspect frc group lower frequenc subject gastrointestin advers reaction compar lixisenatid group higher frequenc subject reaction compar use insulin glargin
223,The incidences of documented hypoglycaemic episode were comparable between the FRC and insulin glargine group.,0,incidences documented hypoglycaemic episode comparable frc insulin glargine group,incid document hypoglycaem episod compar frc insulin glargin group
224,"However, it should be noted that concomitant use of SU was not allowed in the present studies with FRC.",1,however noted concomitant use su allowed present studies frc,howev note concomit use su allow present studi frc
225,Immunological reactions such as allergic reactions and injections site reactions were few and equally distributed between the different treatment groups.,0,immunological reactions allergic reactions injections site reactions equally distributed different treatment groups,immunolog reaction allerg reaction inject site reaction equal distribut differ treatment group
226,A lower frequency of patients developed lixisenatide antibodies (ADA) in the FRC group (36%) compared to the lixisenatide group (48%).,0,lower frequency patients developed lixisenatide antibodies ada frc group compared lixisenatide group,lower frequenc patient develop lixisenatid antibodi ada frc group compar lixisenatid group
227,The RMP adequately reflects the safety concerns listed for the two monocomponents. The,0,rmp adequately reflects safety concerns listed two monocomponents,rmp adequ reflect safeti concern list two monocompon
228,"Overall, the fixed combination of lixisenatide/insulin glargine demonstrates a comparable safety profile as the two mono-components.",0,overall fixed combination lixisenatide insulin glargine demonstrates comparable safety profile two mono components,overal fix combin lixisenatid insulin glargin demonstr compar safeti profil two mono compon
229,There are no major objections based on the efficacy data.,0,major objections based efficacy data,major object base efficaci data
230,"The separate components of the D/C/F/TAF fixed dose combination are already approved, also for use with specific combination.",1,separate components c f taf fixed dose combination already approved also use specific combination,separ compon c f taf fix dose combin alreadi approv also use specif combin
231,Bioequivalence of the FDC to the separate components has been established.,0,bioequivalence fdc separate components established,bioequival fdc separ compon establish
232,"A non-inferior efficacy of D/C/F/TAF vs DRV+COBI+TVD has been shown in the phase 2 study, although a higher than expected discontinuation rate was observed in the D/C/F/TAF group.",1,non inferior efficacy c f taf vs drvcobitvd shown phase study although higher expected discontinuation rate observed c f taf group,non inferior efficaci c f taf vs drvcobitvd shown phase studi although higher expect discontinu rate observ c f taf group
233,Preliminary results from the ongoing phase 3 studies are reassuring in this respect.,0,preliminary results ongoing phase studies reassuring respect,preliminari result ongo phase studi reassur respect
234,The safety profile of the D/C/F/TAF FDC is largely based on the well-established safety profile of the individual components.,0,safety profile c f taf fdc largely based well established safety profile individual components,safeti profil c f taf fdc larg base well establish safeti profil individu compon
235,The safety profile of D/C/F/TAF FDC is supported by the results from the phase 2 study and as well by the preliminary results from the ongoing phase 3 studies.,0,safety profile c f taf fdc supported results phase study well preliminary results ongoing phase studies,safeti profil c f taf fdc support result phase studi well preliminari result ongo phase studi
236,The observed safety profile is in line with expectations and did not raise additional concerns.,0,observed safety profile line expectations raise additional concerns,observ safeti profil line expect rais addit concern
237,"Since Tadalafil Lilly application is an informed consent of Cialis application, the clinical data in support of the Tadalafil Lilly application are identical to the up-to-date clinical data of Cialis dossier, which have been assessed and authorised (including all post-marketing procedures).",0,since tadalafil lilly application informed consent cialis application clinical data support tadalafil lilly application identical date clinical data cialis dossier assessed authorised including post marketing procedures,sinc tadalafil lilli applic inform consent ciali applic clinic data support tadalafil lilli applic ident date clinic data ciali dossier assess authoris includ post market procedur
238,A summary of the literature with regard to clinical data of tadalafil and two bioequivalence studies were provided to demonstrate that the active substance does not differ significantly in properties with regards to safety and efficacy of the reference product and was accepted by the CHMP.,0,summary literature regard clinical data tadalafil two bioequivalence studies provided demonstrate active substance differ significantly properties regards safety efficacy reference product accepted chmp,summari literatur regard clinic data tadalafil two bioequival studi provid demonstr activ substanc differ significantli properti regard safeti efficaci refer product accept chmp
239,"Study TRIPLE 5, triple therapy with BDP/FF/GB (CHF 5993) had a statistically significant and clinically relevant superior effect on pre-dose and 2-h post-dose FEV1 at week 26 than BDP/FF (Foster).",0,study triple triple therapy bdp ff gb chf statistically significant clinically relevant superior effect pre dose h post dose week bdp ff foster,studi tripl tripl therapi bdp ff gb chf statist signific clinic relev superior effect pre dose h post dose week bdp ff foster
240,"TDI focal score, the third co-primary endpoint, had a clinically relevant improvement with both treatments, but the mean difference between treatments in TDI focal score at week 26 was not statistically significant.",1,tdi focal score third co primary endpoint clinically relevant improvement treatments mean difference treatments tdi focal score week statistically significant,tdi focal score third co primari endpoint clinic relev improv treatment mean differ treatment tdi focal score week statist signific
241,"Nevertheless, the responder analysis indicates a benefit for CHF 5993 compared with Foster on TDI symptoms for a greater proportion of patients.",0,nevertheless responder analysis indicates benefit chf compared foster tdi symptoms greater proportion patients,nevertheless respond analysi indic benefit chf compar foster tdi symptom greater proport patient
242,"Also, the observed 23% reduction in the exacerbation rate is above the minimum clinically important difference.",0,also observed reduction exacerbation rate minimum clinically important difference,also observ reduct exacerb rate minimum clinic import differ
243,"Study TRIPLE 6, CHF 5993 had a statistically significant superior effect on moderate and severe COPD exacerbation rate over 52 weeks than Tiotropium.",0,study triple chf statistically significant superior effect moderate severe copd exacerbation rate weeks tiotropium,studi tripl chf statist signific superior effect moder sever copd exacerb rate week tiotropium
244,The observed 20% reduction in the exacerbation rate is above the minimum clinically important difference.,0,observed reduction exacerbation rate minimum clinically important difference,observ reduct exacerb rate minimum clinic import differ
245,Superiority of CHF 5993 pMDI over Tiotropium and non-inferiority relative to Foster pMDI + Tiotropium in terms pre-dose morning FEV1 at Week 52 was also demonstrated.,0,superiority chf pmdi tiotropium non inferiority relative foster pmdi tiotropium terms pre dose morning week also demonstrated,superior chf pmdi tiotropium non inferior rel foster pmdi tiotropium term pre dose morn week also demonstr
246,"The superior clinical efficacy of CHF 5993 pMDI compared to Tiotropium was further supported by consistent findings on other relevant parameters, including SGRQ and use of rescue medication.",0,superior clinical efficacy chf pmdi compared tiotropium supported consistent findings relevant parameters including sgrq use rescue medication,superior clinic efficaci chf pmdi compar tiotropium support consist find relev paramet includ sgrq use rescu medic
247,"For these parameters, CHF 5993 pMDI and Foster pMDI + Tiotropium generally showed a similar effect.",1,parameters chf pmdi foster pmdi tiotropium generally showed similar effect,paramet chf pmdi foster pmdi tiotropium gener show similar effect
248,"Overall, CHF 5993 pMDI has shown benefits in reduction in exacerbation frequency and in improvement in lung function in two large Phase III studies.",0,overall chf pmdi shown benefits reduction exacerbation frequency improvement lung function two large phase iii studies,overal chf pmdi shown benefit reduct exacerb frequenc improv lung function two larg phase iii studi
249,From the safety data presented there are no particular safety signals that suggest an additive effect when FF and GB are administered together.,0,safety data presented particular safety signals suggest additive effect ff gb administered together,safeti data present particular safeti signal suggest addit effect ff gb administ togeth
250,"The main side effects that have been observed with CHF 5993 are associated with the known ICS, LAMA and LABA effects.",1,main side effects observed chf associated known ics lama laba effects,main side effect observ chf associ known ic lama laba effect
251,The clinical database is acceptable and considered sufficient.,0,clinical database acceptable considered sufficient,clinic databas accept consid suffici
252,The clinical safety sections of the SmPC contain appropriate information for each substance and reflect the safety information on the FDC.,0,clinical safety sections smpc contain appropriate information substance reflect safety information fdc,clinic safeti section smpc contain appropri inform substanc reflect safeti inform fdc
253,"In this informed consent application, there are no new issues related to the clinical data. ",0,informed consent application new issues related clinical data,inform consent applic new issu relat clinic data
254,All the clinical data have been assessed for Nuwiq application and adequately reflected in the Product Information.,0,clinical data assessed nuwiq application adequately reflected product information,clinic data assess nuwiq applic adequ reflect product inform
255,SOF/VEL/VOX for 12 weeks has shown excellent efficacy in patients that have previously failed a regimen containing an NS5A inhibitor.,0,sof vel vox weeks shown excellent efficacy patients previously failed regimen containing inhibitor,sof vel vox week shown excel efficaci patient previous fail regimen contain inhibitor
256,A similar 12 week course appears somewhat better than SOF/VEL in patients with previous failure on a DAA-containing regimen without an NS5A inhibitor.,0,similar week course appears somewhat better sof vel patients previous failure daa containing regimen without inhibitor,similar week cours appear somewhat better sof vel patient previou failur daa contain regimen without inhibitor
257,An 8 week course of SOF/VEL/VOX was similarly efficacious as 12 weeks of SOF/VEL in a difficult to cure DAA-naïve cirrhotic GT3 cohort.,0,week course sof vel vox similarly efficacious weeks sof vel difficult cure daa naïve cirrhotic cohort,week cours sof vel vox similarli efficaci week sof vel difficult cure daa naïv cirrhot cohort
258,"Further, an 8 week course of SOF/VEL/VOX showed an SVR rate of 95% in a DAA-naïve population; however, this did not meet predefined non-inferiority with SOF/VEL for 12 weeks.",2,week course sof vel vox showed svr rate daa naïve population however meet predefined non inferiority sof vel weeks,week cours sof vel vox show svr rate daa naïv popul howev meet predefin non inferior sof vel week
259,The addition of VOX appears to increase the barrier to resistance compared to SOF/VEL alone.,1,addition vox appears increase barrier resistance compared sof vel alone,addit vox appear increas barrier resist compar sof vel alon
260,Conclusions concerning recommended use are discussed in the B/R section.,1,conclusions concerning recommended use discussed b r section,conclus concern recommend use discuss b r section
261,"SOF/VEL/VOX has been studied in a sufficient number of patients, including substantial numbers of patients with compensated cirrhosis.",0,sof vel vox studied sufficient number patients including substantial numbers patients compensated cirrhosis,sof vel vox studi suffici number patient includ substanti number patient compens cirrhosi
262,"Compared to SOF/VEL and placebo, there were similar rates of AEs overall, with the only notable difference being increased rates of mild (Grade 1) nausea and diarrhoea.",0,compared sof vel placebo similar rates aes overall notable difference increased rates mild grade nausea diarrhoea,compar sof vel placebo similar rate ae overal notabl differ increas rate mild grade nausea diarrhoea
263,"Other potentially related AE’s including decreased appetite, vomiting, muscle spasms and rash.",1,potentially related aes including decreased appetite vomiting muscle spasms rash,potenti relat ae includ decreas appetit vomit muscl spasm rash
264,"No treatment-related SAE was reported and only one subject (0.1%) in the Phase 3 trials discontinued SOF/VEL/VOX due to reported advents, assessed unrelated to study drug.",0,treatment related sae reported one subject phase trials discontinued sof vel vox due reported advents assessed unrelated study drug,treatment relat sae report one subject phase trial discontinu sof vel vox due report advent assess unrel studi drug
265,"There was no general indication of VOX-associated transaminitis, as has been seen with other NS3/4A inhibitors; however, two cases associated with concomitant ethinyl estradiol among a total of 29 objects exposed, which makes co-administration quite questionable.",2,general indication vox associated transaminitis seen inhibitors however two cases associated concomitant ethinyl estradiol among total objects exposed makes co administration quite questionable,gener indic vox associ transamin seen inhibitor howev two case associ concomit ethinyl estradiol among total object expos make co administr quit question
266,The safety profile of SOF/VEL/VOX for 8 or 12 weeks in patients with compensated liver disease due to HCV infection appears favourable.,0,safety profile sof vel vox weeks patients compensated liver disease due hcv infection appears favourable,safeti profil sof vel vox week patient compens liver diseas due hcv infect appear favour
